10x Genomics, Inc. (TXG)

Market Cap	1.58B
Revenue (ttm)	624.66M
Net Income (ttm)	-157.04M
Shares Out	123.13M
EPS (ttm)	-1.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,958,847
Open	12.37
Previous Close	12.62
Day's Range	12.23 - 13.00
52-Week Range	6.78 - 24.76
Beta	2.03
Analysts	Buy
Price Target	14.13 (+10.39%)
Earnings Date	Aug 7, 2025

About TXG

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, and Spatial Gene and Protein Expression assays, as ...

• Industry: Health Information Services
• Sector: Healthcare
• IPO Date: Sep 12, 2019
• Employees: 1,306
• Stock Exchange: NASDAQ
• Ticker Symbol: TXG
• Website: https://www.10xgenomics.com

Financial Performance

In 2024, 10x Genomics's revenue was $610.79 million, a decrease of -1.28% compared to the previous year's $618.73 million. Losses were -$182.63 million, -28.41% less than in 2023.

Analyst Summary

According to 12 analysts, the average rating for TXG stock is "Buy." The 12-month stock price target is $14.13, which is an increase of 10.39% from the latest price.

Price Target

$14.13

(10.39% upside)

Analyst Consensus: Buy